ストックスクリーナーアプリを入手
1.42
5.96%
-0.09
アフターアワーズ：
1.37
-0.05
-3.52%
前日終値:
$1.51
開ける：
$1.5
24時間の取引高:
72,481
Relative Volume:
0.25
時価総額：
$46.46M
収益：
-
当期純損益:
$-87.23M
株価収益率:
-0.4781
EPS:
-2.97
ネットキャッシュフロー:
$-82.77M
1週間 パフォーマンス:
-14.97%
1か月 パフォーマンス:
-1.39%
6か月 パフォーマンス:
-74.78%
1年 パフォーマンス:
-92.17%
1日の値動き範囲:
$1.415
$1.50
1週間の範囲:
$1.35
$1.67
52週間の値動き範囲:
$0.8801
$19.30
Pepgen Inc Stock (PEPG) Company Profile
PEPG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.42 | 54.64M | 0 | -87.23M | -82.77M | -2.97 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-07-31 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-21 | 開始されました | H.C. Wainwright | Buy |
Pepgen Inc (PEPG) 最新ニュース
Petri Dish: PepGen halts work on Duchenne drug; Needham biotech announces layoffs - The Business Journals
Pepgen pulls plug on exon-skipping therapy for Duchenne MD - Muscular Dystrophy News
PepGen Inc. (NASDAQ:PEPG) Shares Bought by Deutsche Bank AG - Defense World
Leerink Partnrs Forecasts PepGen’s Q3 Earnings (NASDAQ:PEPG) - Defense World
Northern Trust Corp Purchases 7,984 Shares of PepGen Inc. (NASDAQ:PEPG) - Defense World
H.C. Wainwright cuts PepGen stock price target to $8, keeps Buy rating - Investing.com Nigeria
H.C. Wainwright cuts PepGen stock price target to $8, keeps Buy rating By Investing.com - Investing.com South Africa
PepGen price target lowered to $1 from $3 at BofA - Yahoo Finance
PepGen to discontinue DMD programs after PGN-EDO51 did not achieve target - Yahoo Finance
PepGen Inc.’s Strategic Shift to DM1 Program Earns Buy Rating Amid Promising Developments - TipRanks
PepGen (NASDAQ:PEPG) Price Target Lowered to $8.00 at HC Wainwright - Defense World
PepGen Inc. (PEPG) Halts DMD Program After Trial Miss; Shifts Focus to DM1 - MSN
PepGen (PEPG) Adjusts Focus After Discontinuing DMD Program | PE - GuruFocus
PepGen (PEPG) Shifts Focus from DMD as PGN-EDO51 Results Disappo - GuruFocus
PepGen (PEPG) Price Target Lowered by Analyst HC Wainwright & Co. | PEPG Stock News - GuruFocus
PepGen (PEPG) Faces Price Target Cut as Key Program Ends | PEPG Stock News - GuruFocus
PepGen Inc. Receives Buy Rating from Ananda Ghosh Due to Strategic Focus on Promising DM1 Program - TipRanks
PepGen Inc.’s Strategic Shift Amidst DMD Program Discontinuation and Competitive Challenges - TipRanks
PepGen price target lowered to $8 from $14 at H.C. Wainwright - TipRanks
PepGen (PEPG) Shifts Focus from DMD as PGN-EDO51 Results Disappoint | PEPG Stock News - GuruFocus
PepGen (PEPG) Adjusts Focus After Discontinuing DMD Program | PEPG Stock News - GuruFocus
PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate - Benzinga
PepGen to discontinue development of experimental Duchenne therapy; shares drop - whbl.com
PepGen Inc. Discontinues DMD Programs After Trial Results - TipRanks
PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update - Business Wire
PepGen appoints new CTO to advance therapies By Investing.com - Investing.com South Africa
PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer - citybiz
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stoc - GuruFocus
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stock News - GuruFocus
PepGen appoints new CTO to advance therapies - Investing.com
PepGen Inc. (NASDAQ:PEPG) Holdings Lifted by Dimensional Fund Advisors LP - Defense World
PepGen Inc.’s Promising Advances in DMD and DM1 Programs Justify Buy Rating - TipRanks
PepGen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
HC Wainwright Cuts PepGen (NASDAQ:PEPG) Price Target to $14.00 - Defense World
PepGen Inc. Reports Q1 2025 Financial Results - TipRanks
ATTENTION PEPG SHAREHOLDERS: Investors Who Lost Money on PepGen Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire
PepGen stock price target cut to $14 from $16 by H.C. Wainwright - Investing.com Nigeria
PepGen (PEPG) Stock Target Price Lowered by HC Wainwright & Co. - GuruFocus
PepGen (PEPG) Price Target Adjusted by H.C. Wainwright Analyst | PEPG Stock News - GuruFocus
PepGen (PEPG) Price Target Adjusted by H.C. Wainwright Analyst | - GuruFocus
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - BioSpace
PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Pepgen Inc (PEPG) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
1.24%
大文字化:
|
ボリューム (24 時間):